Healthcare & Medical Devices Global On demand · 24-48h

Global Blood Glucose Testing Equipment Market Strategic Research Report

Global Blood Glucose Testing Equipment Market Strategic Rese…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Blood Glucose Testing Equipment Market
$17.29B2025
6.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Self-Monitoring Blood Glucose Systems, Continuous Glucose Monitoring Systems, Flash Glucose Monitoring Systems, Professional Point-of-Care Glucose Systems, Others

By Application: Home & Self-Care, Hospitals & Clinics, Long-Term Care & Nursing Facilities, Diagnostic & Health-Management Centers, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Abbott Laboratories, DexCom, Inc., F. Hoffmann-La Roche Ltd, LifeScan, Inc., Ascensia Diabetes Care Holdings AG, Medtronic plc, ARKRAY, Inc., i-SENS, Inc., Nova Biomedical Corporation, ACON Laboratories, Inc., Sinocare Inc., Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., Shenzhen SIBIONICS Technology Co., Ltd., MicroTech Medical (Hangzhou) Co., Ltd., VivaChek Biotech (Hangzhou) Co., Ltd., Beijing Yicheng Bioelectronics Technology Co., Ltd., Sejoy Biomedical Co., Ltd., TaiDoc Technology Corporation

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 132 pages
Market size 2025
$17.29B
Billion USD
Forecast CAGR
6.8%
2025-2032
Forecast 2032
$27.4B
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

Scope of the Report

The global Blood Glucose Testing Equipment market size is predicted to grow from US$ 17,286 million in 2025 to US$ 27,503 million in 2032; it is expected to grow at a CAGR of 6.8% from 2026 to 2032.

Blood Glucose Monitoring Equipment comprises regulated in vitro diagnostic and wearable medical devices used to quantitatively measure blood glucose or continuously estimate glucose concentrations in interstitial fluid. The principal product categories are self-monitoring blood glucose systems, continuous glucose monitoring systems and professional point-of-care glucose monitoring systems. A typical system includes a meter or reader, disposable test strips or glucose sensors, sampling and calibration accessories, data-transmission modules and supporting software.

The market scope includes regulated SMBG, CGM and professional POC devices and their dedicated consumables, including meters, readers, strips, sensors, transmitters, lancets and control solutions. It excludes central laboratory chemistry analyzers, HbA1c analyzers, insulin pumps, standalone blood-ketone devices and consumer electronic products claiming non-invasive glucose measurement through watches, optical sensors or radio-frequency technology without appropriate medical-device authorization.

In 2025, global shipments of Blood Glucose Testing Equipment are estimated at 60 million sets, with a price of approximately US$280 per set and a gross profit margin of approximately 45%-65%.

The expanding global population living with diabetes provides a stable and recurring demand base for glucose monitoring equipment. Higher screening rates, population ageing and rising obesity prevalence are supporting demand in home self-management, primary care and hospital point-of-care testing. CGM use is expanding beyond people with type 1 diabetes and intensive insulin therapy toward broader populations with type 2 diabetes, gestational diabetes and selected high-risk metabolic conditions. Wider reimbursement, longer sensor wear and direct smartphone connectivity are expected to reduce barriers to adoption.

Major constraints include unequal reimbursement, the cumulative cost of consumables, analytical accuracy, interference control, data privacy and interoperability. Conventional SMBG faces pricing pressure from procurement programs, retail competition and low-cost OEM products, with low-priced or free meters increasingly used to generate recurring strip sales. CGM suppliers must continue to address sensor adhesion, skin reactions, physiological lag between blood and interstitial glucose, performance at extreme glucose levels and compatibility with mobile devices and insulin-delivery systems. Unapproved non-invasive glucose watches also create consumer confusion and potential patient-safety risks.

Market value will increasingly concentrate in recurring sensors, test strips, algorithms and data services. CGM will remain the fastest-growing segment, but SMBG will continue to play an essential role in lower-income markets, primary care, infrequent testing, confirmation of unexpected CGM readings and acute clinical situations. Hospitals will place greater emphasis on multi-patient infection control, hematocrit and drug-interference correction, operator identification and connectivity with HIS, LIS and electronic medical records. Suppliers combining biosensor intellectual property, high-volume consumable manufacturing, clinical evidence, reimbursement access and digital management platforms will hold the strongest competitive positions.

This report presents a comprehensive overview of the global Blood Glucose Testing Equipment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Self-Monitoring Blood Glucose Systems
  • Continuous Glucose Monitoring Systems
  • Flash Glucose Monitoring Systems
  • Professional Point-of-Care Glucose Systems
  • Others

Segment by User Group

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Others

Segment by Distribution Channel

  • Retail Pharmacies
  • Hospital & Clinic Procurement
  • E-Commerce
  • Diabetes Specialty Clinics & Centers
  • Others

Segment by Application

  • Home & Self-Care
  • Hospitals & Clinics
  • Long-Term Care & Nursing Facilities
  • Diagnostic & Health-Management Centers
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Blood Glucose Testing Equipment market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Home & Self-Care, Hospitals & Clinics, Long-Term Care & Nursing Facilities evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Blood Glucose Testing Equipment Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$17.29B
2025
Forecast
$27.4B
2032
CAGR
6.8%
2025–2032
영역들
5
global
Key companies
Abbott LaboratoriesDexCom, Inc.F. Hoffmann-La Roche LtdLifeScan, Inc.Ascensia Diabetes Care Holdings AGMedtronic plcARKRAY, Inc.i-SENS, Inc.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Self-Monitoring Blood Glucose SystemsContinuous Glucose Monitoring SystemsFlash Glucose Monitoring SystemsProfessional Point-of-Care Glucose SystemsOthers
By Application
Home & Self-CareHospitals & ClinicsLong-Term Care & Nursing FacilitiesDiagnostic & Health-Management CentersOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Self-Monitoring Blood Glucose Systems
  • 3.1.3 Continuous Glucose Monitoring Systems
  • 3.1.4 Flash Glucose Monitoring Systems
  • 3.1.5 Professional Point-of-Care Glucose Systems
  • 3.1.6 Others
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Home & Self-Care
  • 4.1.3 Hospitals & Clinics
  • 4.1.4 Long-Term Care & Nursing Facilities
  • 4.1.5 Diagnostic & Health-Management Centers
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Abbott Laboratories
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 DexCom, Inc.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 F. Hoffmann-La Roche Ltd
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 LifeScan, Inc.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Ascensia Diabetes Care Holdings AG
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Medtronic plc
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 ARKRAY, Inc.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 i-SENS, Inc.
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Nova Biomedical Corporation
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 ACON Laboratories, Inc.
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Sinocare Inc.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Shenzhen SIBIONICS Technology Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 MicroTech Medical (Hangzhou) Co., Ltd.
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 VivaChek Biotech (Hangzhou) Co., Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Beijing Yicheng Bioelectronics Technology Co., Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Sejoy Biomedical Co., Ltd.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 TaiDoc Technology Corporation
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Blood Glucose Testing Equipment market?
The global Blood Glucose Testing Equipment market is estimated at US$ 17.29 billion in 2025 (base year) and is projected to reach US$ 27.5 billion by 2032.
What is the forecast CAGR for the Blood Glucose Testing Equipment market?
The market is expected to grow at a CAGR of 6.8% from 2026 to 2032, expanding from US$ 17.29 billion in 2025 to US$ 27.5 billion in 2032, roughly 1.6 times its base-year value.
What is Blood Glucose Testing Equipment?
Blood Glucose Monitoring Equipment comprises regulated in vitro diagnostic and wearable medical devices used to quantitatively measure blood glucose or continuously estimate glucose concentrations in interstitial fluid. The principal product categories are self-monitoring blood glucose systems, continuous glucose monitoring systems and professional point-of-care glucose monitoring systems.
What are the main segments of the Blood Glucose Testing Equipment market by type?
By type, the market is segmented into Self-Monitoring Blood Glucose Systems, Continuous Glucose Monitoring Systems, Flash Glucose Monitoring Systems, Professional Point-of-Care Glucose Systems and Others.
Which applications drive demand in the Blood Glucose Testing Equipment market?
Key applications covered include Home & Self-Care, Hospitals & Clinics, Long-Term Care & Nursing Facilities, Diagnostic & Health-Management Centers and Others.
Who are the key players in the Blood Glucose Testing Equipment market?
Key players profiled include Abbott Laboratories, DexCom, F. Hoffmann-La Roche Ltd, LifeScan, Ascensia Diabetes Care Holdings AG, Medtronic plc, ARKRAY and i-SENS, among 18 companies covered in total.
Which regions and countries are covered for Blood Glucose Testing Equipment?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What challenges does the Blood Glucose Testing Equipment market face?
Wider reimbursement, longer sensor wear and direct smartphone connectivity are expected to reduce barriers to adoption.
Who should buy the Blood Glucose Testing Equipment market report?
The report is intended for manufacturers and solution providers, distributors and end users in Home & Self-Care, Hospitals & Clinics and Long-Term Care & Nursing Facilities, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Blood Glucose Testing Equipment market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.